Avalo Therapeutics, Inc. (AVTX)

NASDAQ: AVTX · Real-Time Price · USD

7.76

+0.06 (0.78%)

At close: Nov 13, 2026, 4:00 PM EST

7.55

-0.21 (-2.71%)

After-hours: Nov 13, 2026, 7:30 PM EST

Avalo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	64.99	15.86	134.55	7.42	13.17	54.59
Short-Term Investments	327.98	82.48	-	-	-	-
Cash & Short-Term Investments	392.97	98.34	134.55	7.42	13.17	54.59
Cash Growth	252.07%	-26.91%	1714.51%	-43.71%	-75.87%	188.52%
Accounts Receivable	-	-	-	-	-	1.06
Other Receivables	-	-	-	0.14	1.92	3.74
Receivables	-	-	-	0.14	1.92	4.8
Inventory	-	-	-	-	0.02	0.04
Prepaid Expenses	7.56	6.91	4.33	0.84	1.29	2.37
Restricted Cash	0.21	0.04	0.02	0	0.02	0.05
Total Current Assets	400.74	105.29	138.89	8.4	16.42	61.85
Property, Plant & Equipment	0.2	0.46	1.21	1.97	2.41	2.7
Goodwill	10.5	10.5	10.5	10.5	14.41	14.41
Other Intangible Assets	-	-	-	-	-	0.04
Other Long-Term Assets	0.18	0.21	0.13	0.13	0.13	1.23
Total Assets	481.43	116.46	150.73	20.99	33.37	80.21

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2.46	0.14	0.28	0.45	2.88	3.37
Accrued Expenses	21.48	12.41	5.22	1.76	10.51	14.29
Current Portion of Long-Term Debt	-	-	-	-	5.93	-
Current Portion of Leases	0.15	0.39	0.57	0.54	0.53	0.49
Current Unearned Revenue	-	-	-	-	0.09	-
Other Current Liabilities	-	-	0.89	1.87	2.17	1.74
Total Current Liabilities	24.09	12.94	6.96	4.62	22.11	19.89
Long-Term Debt	-	-	-	-	13.49	32.83
Long-Term Leases	-	0.04	0.35	1.37	1.71	2.02
Long-Term Deferred Tax Liabilities	0.47	0.43	0.27	0.16	0.14	0.11
Other Long-Term Liabilities	20.32	20	10.12	7.55	6.83	2.28
Total Liabilities	44.88	33.41	17.7	13.69	44.28	57.13

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.05	0.02	0.01	0	-	0.01
Additional Paid-In Capital	961.46	531.49	503.29	342.44	292.91	285.24
Retained Earnings	-523.46	-448.52	-370.26	-335.13	-303.82	-262.17
Comprehensive Income & Other	-1.51	0.07	-	-	-	-
Shareholders' Equity	436.55	83.05	133.03	7.3	-10.92	23.08
Total Liabilities & Equity	481.43	116.46	150.73	20.99	33.37	80.21

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	0.15	0.43	0.92	1.9	21.66	35.34
Net Cash (Debt)	392.81	97.91	133.63	5.51	-8.49	19.25
Net Cash Growth	253.69%	-26.73%	2324.31%	-	-	10.28%
Net Cash Per Share	11.44	7.30	17.83	19.85	-216.49	531.87
Filing Date Shares Outstanding	57.82	22.79	10.67	1.03	0.06	0.04
Total Common Shares Outstanding	53.92	18.51	10.47	0.8	0.04	0.04
Working Capital	376.64	92.35	131.93	3.78	-5.7	41.96
Book Value Per Share	8.10	4.49	12.70	9.11	-277.78	589.35
Tangible Book Value	426.04	72.55	122.53	-3.2	-25.32	8.64
Tangible Book Value Per Share	7.90	3.92	11.70	-3.99	-644.47	220.48
Machinery	-	0.14	0.28	0.28	0.34	0.24
Leasehold Improvements	-	0.24	0.9	0.9	0.74	0.74

SEC Filings: 10-K · 10-Q